Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$12.95 - $49.69 $551,488 - $2.12 Million
-42,586 Reduced 14.06%
260,379 $4.61 Million
Q2 2021

Aug 17, 2021

BUY
$25.57 - $44.88 $2.58 Million - $4.53 Million
100,831 Added 49.88%
302,965 $13.6 Million
Q1 2021

May 17, 2021

BUY
$19.02 - $31.15 $3.84 Million - $6.3 Million
202,134 New
202,134 $5.24 Million
Q2 2020

Aug 13, 2020

SELL
$6.19 - $18.84 $3.26 Million - $9.91 Million
-526,075 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$5.4 - $9.22 $561,195 - $958,188
-103,925 Reduced 16.5%
526,075 $3.71 Million
Q4 2019

Feb 13, 2020

BUY
$4.69 - $13.45 $2.95 Million - $8.47 Million
630,000 New
630,000 $4.44 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Sphera Funds Management Ltd. Portfolio

Follow Sphera Funds Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.